![](https://investorshub.advfn.com/uicon/811563.png?cb=1634766285)
Sunday, May 15, 2022 7:32:27 PM
cancerdiscovery@aacr.org
Article correction for DC-Vax L
At New York Academy of Sciences on May 10, 2022 there was a scientific presentation of DC-Vax L which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack the cancer. DC-Vax L showed amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. Both the primary and secondary endpoints for overall survival inn new and recurrent GBM patients were statistically significant.
Below is a link to the Phase III trial results. Please have your article rewritten yesterday to reflect the positive results of DC-Vax L as well as a retraction of the incorrect statistics included in your article. The article reflects an incorrect data analysis. I would suggest talking to Dr. Mulholland or Dr. Liau to confirm the accurate results as well as the information provided that progression free survival (pfs) is no longer an effective assessment with regards to GBM trials.
This company is also working on a cancer platform to treat a broad variety of cancers in the future. Northwest Biotherapeutics is trying to bring effective cancer treatments to the world and this is news worthy.
Do you want to be part of the problem and stock price manipulation or do you want to report the truth?
Thank you for your time in reviewing the data, correcting the article and publishing a retraction.
Margaret Monson
https://virtualtrials.org/dcvax/dcvax.pdf
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM